Zyden Gentec - Royalty Agreement with Changshu Wanxing Chemical

Zyden Gentec Ltd has announced that the Company has successfully completed the Technology Transfer for the Synthesis of Iminostilbenes, an intermediate widely used in different Tricycle Anti-depressants to Changshu Wanxing Chemical Company Ltd of China.

Under the terms of the agreement, Changshu Wanxing Chemical Company Ltd will pay the Company a royalty of 2% on the gross sales of the product. The Chinese company expects a sale of US $ 8 to 10 Millions per annum out of this product.

Meanwhile the company has also successfully developed technology for the Synthesis of Anti-viral drug Tamiflu. The company is now looking for partners to market the drug internationally.

Source : Equity Bulls

Keywords